17 allylamino-17-demethoxygeldanamycin
Nodular Sclerosis Classical Hodgkin Lymphoma
Explore 8 assets in Nodular Sclerosis Classical Hodgkin Lymphoma →Floatz Rating
B57/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
UNKNOWN
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00082966CT.gov Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Nodular Sclerosis Classical Hodgkin Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| 17 allylamino-17-demethoxygeldanamycin (this asset) | National Cancer Institute (NCI) | P2 | B · 57 |
| Etoposide | Northwestern University | P3 | BB |
| Nivestim | National Cancer Institute (NCI) | P3 | BB |
| Adriamycin | National Cancer Institute (NCI) | P3 | BB |
| Isocyclophosphamide | Northwestern University | P3 | BB |
| Bleomycin | City of Hope Medical Center | P3 | BB |
| Vinorelbine Ditartrate | National Cancer Institute (NCI) | P3 | BB |
| Dexasone | Children's Oncology Group | P3 | BB |
| Prednisone | Children's Oncology Group | P3 | BB |
+20 more in the Nodular Sclerosis Classical Hodgkin Lymphoma cohort
Other indications for 17 allylamino-17-demethoxygeldanamycin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hodgkin'S Lymphoma, Mixed Cellularity | — | P2 | B · 57 |
| Von Hippel-Lindau Disease | — | P2 | B · 57 |
| Hodgkins Lymphoma | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. 17 allylamino-17-demethoxygeldanamycin in Nodular Sclerosis Classical Hodgkin Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/17-allylamino-17-demethoxygeldanamycin-nodular-sclerosis-classical-hodgkin-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →